Related Experiment Video
Updated: Jan 22, 2026

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
Immunosuppressive therapy in children with primary nephrotic syndrome: single center experience, Karachi, Pakistan
Khemchand Netaram Moorani1,2, Harnam Moolchand Hotchandani3, Aasia Mohammad Zubair4,3
1Department of Pediatric Nephrology, National Institute of Child Health (NICH), Jinnah Sindh Medical University, Karachi, Pakistan. khemchandn@hotmail.com.
Insights
Treatment for difficult nephrotic syndrome in children involves various immunosuppressive agents. Levamisole and cyclophosphamide effectively maintain remission in frequent relapsing/steroid-dependent cases, while cyclosporine aids remission in steroid-resistant nephrotic syndrome.
Area of Science:
- Pediatric Nephrology
- Immunosuppressive Therapy
- Nephrotic Syndrome
Background:
- Nephrotic syndrome in children is often steroid-sensitive, but difficult-to-treat cases (frequent relapsing, steroid-dependent, steroid-resistant) pose therapeutic challenges.
- Common treatment options include low-dose steroids, levamisole, cyclophosphamide (CPM), mycophenolate mofetil (MMF), and calcineurin inhibitors (CNIs).
Purpose of the Study:
- To evaluate the efficacy of steroid therapy and alternative immunosuppressive agents (ISAs) in children diagnosed with difficult nephrotic syndrome (DNS).
Main Methods:
- A retrospective cohort study included 176 children with DNS managed over 12 years (2005-2017).
- Treatment protocols involved initial oral prednisolone (OP), followed by low-dose OP, levamisole, or cyclophosphamide for frequent relapsing/steroid-dependent cases.
- Steroid-resistant cases and non-responders to levamisole/cyclophosphamide underwent biopsy and were treated with CNIs and MMF.
Main Results:
- The study identified 130 (73.86%) children with frequent relapsing/steroid-dependent (FR/SD) and 46 (26.13%) with steroid-resistant nephrotic syndrome (SRNS).
- Minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) were the primary histological findings.
- Levamisole showed 80% effectiveness, CPM achieved 57.77% complete remission (CR) and 22.22% partial remission (PR), cyclosporine (CS) induced 46.59% CR and 39.77% PR, and MMF resulted in 69% PR and 12.82% CR.
- At follow-up, 46% maintained remission off-treatment, 35% on therapy, 5.68% progressed to chronic kidney disease, and mortality was 2.84%.
Conclusions:
- Levamisole and cyclophosphamide are effective in maintaining remission for FR/SD nephrotic syndrome.
- Cyclosporine demonstrates efficacy in inducing remission for SRNS.
- FSGS is a significant factor contributing to resistance against both steroid and alternative ISAs.
Background:
Majority of children with nephrotic syndrome are steroid sensitive, but treatment of difficult to treat nephrotic (frequent relapsing, steroid dependent and steroid resistant) syndrome is challenging. Low dose steroid, levamisole, cyclophosphamide (CPM), mycophenolate mofetil (MMF) and calcineurin inhibitors (CNIs) are the common options of treatment. Objective of the study was to determine the response to steroid and alternative immunosuppressive agents (ISAs) in children with difficult nephrotic syndrome (DNS).
Methods:
This is a retrospective cohort study of 176 children with DNS, managed over 12 years at The Kidney Center-Postgraduate Training Institute, Karachi- Pakistan from 2005 to 2017. Initial episode was treated with daily oral prednisolone (OP) for 4-8 weeks followed by alternate day OP for 12-24 weeks. Subsequently low dose OP, levamisole (Leva)and cyclophosphamide was used for frequent relapsing (FR)/ steroid dependent (SD). All with initial steroid resistance and non- responders to leva and or cyclophosphamide were biopsied and treated with CNIs and MMF. Data was analyzed using descriptive statistics.
Results:
There were 130(73.86%) children with FR/SD and 46(26.13%) with SRNS. All children with SR (46) and 86 with FR/SD were biopsied. Minimal change disease (60.60%) and focal segmental glomerulosclerosis (FSGS 23%) were the two common lesions. Majority (73.86%) received single OP whereas divided doses were administered in 26.13% cases. Daily OP was used for 4, 6 and 8 weeks in 61.36,28.4 and10.22% respectively. Steroids were tapered over 3 (31.81%),4 (52.27%) and 6 months (15.90%). Levamisole, CPM, cyclosporin (CS) and MMF were used sequentially in 45, 54.23, 50 and 20% respectively. Combination of MMF and CS was used in 11.29% of cases. Levamisole was effective in 80%, CPM induced complete remission (CR, 57.77%) or partial remission (PR, 22.22%), CS induced CR 46.59% and PR 39.77%. MMF showed PR and CR 69 and 12.82% respectively. At last follow up, 46% were maintaining remission while off treatment, whereas 35% are maintaining remission on therapy,10.23% lost- to-follow, 5.68% progressed to chronic kidney disease. Mortality was 2.84% and it was due to infection and uremia.
Conclusion:
Majority had steroid sensitive MCD. Levamisole and cyclophosphamide were effective in maintaining remission in FR/ SD. FSGS was responsible for resistance to steroid and alternative ISAs. Cyclosporin was effective in inducing remission in SRNS. Mortality was less than 3%.
Related Concept Videos
Nephrotic Syndrome I : Introduction
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Lattice Centering and Coordination Number
Types of Unit Cells
Imagine taking a large number of identical...
Center of Gravity
Center of Gravity
To determine its location, the principle of moments can be utilized by dividing the object into...

